Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Spot gold has risen by 1% intraday, with the current price at $4,017.13 per ounce. As a precious metal highly watched by global investors, gold price fluctuations are closely linked to multiple factors such as global geopolitical situations, inflation levels, and major economies' monetary policies. This intraday increase has also attracted the attention of many market participants.

Spot gold has risen by 1% intraday, with the current price at $4,017.13 per ounce. As a precious metal highly watched by global investors, gold price fluctuations are closely linked to multiple factors such as global geopolitical situations, inflation levels, and major economies' monetary policies. This intraday increase has also attracted the attention of many market participants.

智通财经智通财经2026/07/17 16:16
Show original
Spot gold rose by 1% intraday, currently quoted at $4,017.13 per ounce. As a precious metal closely watched by global investors, gold price fluctuations are typically closely linked to multiple factors such as global geopolitical events, inflation levels, and the monetary policy directions of major economies. This intraday increase has attracted significant attention from market participants.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds